Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Fasudil attenuates aggregation of α-synuclein in models of Parkinson's disease.

Acta neuropathologica communications - 22 Apr 2016

Tatenhorst Lars, Eckermann Katrin, Dambeck Vivian, Fonseca-Ornelas Luis, Walle Hagen, Lopes da Fonseca Tomás, Koch Jan C, Becker Stefan, Tönges Lars, Bähr Mathias, Outeiro Tiago F, Zweckstetter Markus, Lingor Paul

Abstract excerpt

Parkinson's disease (PD) is the most common neurodegenerative movement disorder, yet disease-modifying treatments do not currently exist. Rho-associated protein kinase (ROCK) was recently described as a novel neuroprotective target in PD. Since alpha-synuclein (α-Syn) aggregation is a major hallmark in the pathogenesis of PD, we aimed to evaluate the anti-aggregative potential of pharmacological ROCK inhibition...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to alpha-Synuclein
Share to Amides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Enzyme Inhibitors

Share to Protein Aggregates

Share to Psychomotor Performance

Share to Pyridines

Share to Recognition, Psychology

Share to Tyrosine 3-Monooxygenase

Source

Open in PubMed Open full text

Identifiers

PMID: 27101974
DOI: 10.1186/s40478-016-0310-y
PMCID: PMC4840958

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Fasudil attenuates aggregation of α-synuclein in models of Parkinson's disease.PMID 27101974Read ↗

The good and bad of therapeutic strategies that directly target α‐synucleinSemantic proximity Read ↗

Apoptosis signal-regulating kinase 1 modulates the phenotype of α-synuclein transgenic mice.Semantic proximity Read ↗

Extracellular α-synuclein induces sphingosine 1-phosphate receptor subtype 1 uncoupled from inhibitory G-protein leaving β-arrestin signal intact.Semantic proximity Read ↗

The therapeutic potential of LRRK2 and alpha-synuclein in Parkinson's disease.Semantic proximity Read ↗

A <i>de novo</i> compound targeting α-synuclein improves deficits in models of Parkinson's diseaseSemantic proximity Read ↗

α-Synuclein interacts with the switch region of Rab8a in a Ser129 phosphorylation-dependent manner.Semantic proximity Read ↗

Mitochondrial division inhibitor-1 is neuroprotective in the A53T-α-synuclein rat model of Parkinson's disease.Semantic proximity Read ↗

Suppression and modulation mechanism underlying the flavonoid-induced inhibition of fibrillation of α-synucleinSemantic proximity Read ↗

Aberrant adenosine A2A receptor signaling contributes to neurodegeneration and cognitive impairments in a mouse model of synucleinopathy.Semantic proximity Read ↗

Rational design of small molecules able to inhibit α-synuclein amyloid aggregation for the treatment of Parkinson’s diseaseSemantic proximity Read ↗

Alpha-Synuclein transgenic mice, h-α-SynL62, display α-Syn aggregation and a dopaminergic phenotype reminiscent of Parkinson's disease.Semantic proximity Read ↗

The C-terminal fragment of LRRK2 with the G2019S substitution increases the neurotoxicity of mutant A53T α-synuclein in dopaminergic neurons in vivoSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.